Mandate

Vinge has advised EQT in connection with the combination with Baring Private Equity Asia

Vinge has advised EQT in connection with the combination with Baring Private Equity Asia, a leading private markets investment firm in Asia with EUR 17.7bn of assets under management. The total consideration amounts to EUR 6.8bn.

Through the transaction, EQT will acquire 100 percent of the BPEA management company, the BPEA general partner entities which control the BPEA funds, and the right to carried interest in selected existing funds. The total consideration amounts to EUR 6.8bn, of which approximately EUR 5.3bn to be paid through the issue of 191.2 million new EQT ordinary shares (corresponding to a dilution of approximately 16%), plus EUR 1.5 billion in cash. The transaction is subject to customary closing conditions and the completion is expected to be carried out during the fourth quarter of 2022.

Vinge’s team mainly consists of Sofie Bjärtun, Erik Sjöman, Linnéa Sellström, Joel Magnusson, Lorin Arabi, Pernilla Björklund, Marcus GladerEmma Johansson, Sebastian Örndahl, Jesper Ekman and Adam Löfquist

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025